Nitrogen Bonded Directly To The 1,3-diazine At 2-position By A Single Bond Patents (Class 514/275)
-
Patent number: 10201540Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.Type: GrantFiled: March 2, 2017Date of Patent: February 12, 2019Assignee: Frequency Therapeutics, Inc.Inventors: Christopher Loose, Will McLean, Megan Harrison, Michael R. Jirousek
-
Patent number: 10189833Abstract: Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized: Also provided are methods of using the solid forms.Type: GrantFiled: October 4, 2017Date of Patent: January 29, 2019Assignee: Plexxikon Inc.Inventors: Prabha N. Ibrahim, Gary Conard Visor
-
Patent number: 10150743Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: May 11, 2016Date of Patent: December 11, 2018Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Patent number: 10130719Abstract: The present invention relates to compounds which are salts of specialized pro-resolving mediators (referred to herein as “SPMs”) which include lipoxins, resolvins, protectins, and their aspirin-triggered counterparts. The SPM salts described here contain at least one or two SPM molecules ionically bound to at least one basic function that is provided by a scaffold moiety as described herein, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.Type: GrantFiled: June 2, 2017Date of Patent: November 20, 2018Assignee: Thetis Pharmaceuticals LLCInventors: Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, Jr., Jessica J. Dworak
-
Patent number: 10131639Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.Type: GrantFiled: September 18, 2017Date of Patent: November 20, 2018Assignee: Signal Pharmaceuticals, LLCInventors: Nathan Andrew Boersen, Indrajit Ghosh, Lianfeng Huang, Daozhong Zou
-
Patent number: 10111845Abstract: There is herein provided valproic acid, or a pharmaceutically acceptable salt, thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.Type: GrantFiled: October 8, 2015Date of Patent: October 30, 2018Assignee: Cereno Scientific ABInventors: Sverker Jern, Jonas Faijerson Saljo, Niklas Bergh
-
Patent number: 10111894Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.Type: GrantFiled: March 23, 2018Date of Patent: October 30, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10092581Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as Modic changes type 1.Type: GrantFiled: January 24, 2018Date of Patent: October 9, 2018Assignee: ANTECIP BIOVENTURES II LLCInventors: Herriot Tabuteau, Jaro I. Karppinen
-
Patent number: 10080751Abstract: Therapeutic methods, kits, dosing regimens and uses of a medicament comprising iclaprim are provided, for example, for the treatment of bacterial infection. The administration of iclaprim in a fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The bacterial infection treated may be caused, or related to, drug-resistant bacteria including S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M. catarrhalis. The bacterial infection may manifest as a skin and skin structure infection, pneumonia, asthma, emphysema and/or other adverse pulmonary conditions.Type: GrantFiled: May 4, 2017Date of Patent: September 25, 2018Assignee: Motif Biosciences Inc.Inventor: David Huang
-
Patent number: 10076522Abstract: Therapeutic methods, kits, dosing regimens and uses as medicament are provided, for example, for the treatment of bacterial infection. The therapeutic methods can comprise intravenously administering to a subject who has a bacterial infection a pharmaceutical composition comprising a fixed amount of iclaprim. The administration of the fixed amount can achieve a Cmax(ss) below about 800 ng/mL, a T>MIC of between about 30% to about 95% and a ratio of AUC/MIC of about 20 to about 85, and the bacterial infection can be treated. The fixed amount can be about 70 mg to about 100 mg. The pharmaceutical composition can be infused into the subject about 1 to about 3 times a day daily over a time period of about 0.75 hours to about 4 hours.Type: GrantFiled: May 3, 2017Date of Patent: September 18, 2018Assignee: Motif Biosciences Inc.Inventors: David Huang, Keith A. Bostian, William G. Kramer
-
Patent number: 10065964Abstract: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.Type: GrantFiled: December 13, 2016Date of Patent: September 4, 2018Assignee: Ziarco Pharma Ltd.Inventors: Gavin A. Whitlock, Paul Alan Glossop
-
Patent number: 10059690Abstract: The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.Type: GrantFiled: October 31, 2017Date of Patent: August 28, 2018Assignee: Syros Pharmaceuticals, Inc.Inventors: Stephane Ciblat, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li, Michael Bradley, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Jason J. Marineau, Tom Miller, Stephanie Roy, Darby Schmidt, M. Arshad Siddiqui
-
Patent number: 10059688Abstract: Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.Type: GrantFiled: September 1, 2017Date of Patent: August 28, 2018Assignee: BETTA PHARMACEUTICALS CO., LTD.Inventors: Shaojing Hu, Xiangyong Liu, Jinlong Bai, Wei Long
-
Patent number: 10059706Abstract: Disclosed are compounds of formula (I) which possess nematicidal properties wherein the structural elements have the meaning as indicated in the description.Type: GrantFiled: May 5, 2015Date of Patent: August 28, 2018Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Klaus-Helmut Mueller, Susanne Kuebbeler, Joerg Greul, Daniela Portz, Olga Malsam, Kerstin Ilg
-
Patent number: 10053458Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.Type: GrantFiled: May 21, 2015Date of Patent: August 21, 2018Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
-
Patent number: 10045987Abstract: The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides nilotinib analogs that provide therapeutic benefits.Type: GrantFiled: August 27, 2015Date of Patent: August 14, 2018Assignee: Codexis, Inc.Inventors: Gjalt W. Huisman, Jed Lee Hubbs, Xiyun Zhang, Robert Osborne
-
Patent number: 10034890Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: September 6, 2017Date of Patent: July 31, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10028503Abstract: Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 2015Date of Patent: July 24, 2018Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Yi Zheng, Jose Cancelas
-
Patent number: 10028969Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: November 16, 2017Date of Patent: July 24, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10028908Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: November 7, 2017Date of Patent: July 24, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10023567Abstract: Compounds having General Formula (I) or General Formula (II): in which R1 is chosen from C1 to C10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof; R2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties substituted heteroaromatic moieties, and coumarin; R3 is chosen from —H, C1 to C10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.Type: GrantFiled: May 6, 2015Date of Patent: July 17, 2018Assignee: Ohio UniversityInventors: Douglas Goetz, Stephen C. Bergmeier, Mark C. McMills, Crina M. Orac
-
Patent number: 10016445Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: November 9, 2017Date of Patent: July 10, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10016423Abstract: A solid form of Nilotinib hydrochloride, which exists as a co-crystal of nilotinib hydrochloride and levulinic acid having a molar ratio of nilotinib hydrochloride to levulinic acid of 1:2, and a process for the preparation of the co-crystal.Type: GrantFiled: October 15, 2015Date of Patent: July 10, 2018Assignee: Apotex Inc.Inventors: Matthew Pompili, David A. Stradiotto, Probal Kanti Datta
-
Patent number: 10016405Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.Type: GrantFiled: September 6, 2016Date of Patent: July 10, 2018Assignee: Constellation Pharmaceuticals, Inc.Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
-
Patent number: 9994570Abstract: The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 20, 2015Date of Patent: June 12, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Thomas S. Reger, Anthony J. Roecker
-
Patent number: 9969726Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.Type: GrantFiled: June 9, 2015Date of Patent: May 15, 2018Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler
-
Patent number: 9956156Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C8-C24 alcohol ester of a carboxylic acid.Type: GrantFiled: March 27, 2017Date of Patent: May 1, 2018Assignee: Johnson & Johnson Consumer Inc.Inventor: Jeffrey M Wu
-
Patent number: 9949993Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as chronic low back pain.Type: GrantFiled: June 14, 2017Date of Patent: April 24, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9951050Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.Type: GrantFiled: June 18, 2014Date of Patent: April 24, 2018Assignee: 4 SC AGInventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
-
Patent number: 9943531Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as Modic changes type I.Type: GrantFiled: April 11, 2017Date of Patent: April 17, 2018Assignee: ANTECIP BIOVENTURES II LLCInventors: Herriot Tabuteau, Jaro I. Karppinen
-
Patent number: 9937176Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.Type: GrantFiled: September 2, 2015Date of Patent: April 10, 2018Assignee: NIPPON SHINYAKU CO., LTD.Inventors: Yoshinobu Shiba, Satoshi Akiyama
-
Patent number: 9932325Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.Type: GrantFiled: October 25, 2017Date of Patent: April 3, 2018Assignee: Denali Therapeutics Inc.Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
-
Patent number: 9932320Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.Type: GrantFiled: January 23, 2015Date of Patent: April 3, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
-
Patent number: 9920044Abstract: This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.Type: GrantFiled: July 22, 2015Date of Patent: March 20, 2018Assignee: RADIUS PHARMACEUTICALS, INC.Inventor: Chris P. Miller
-
Patent number: 9895369Abstract: The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.Type: GrantFiled: September 20, 2016Date of Patent: February 20, 2018Assignee: FORSIGHT VISION4, INCInventors: Judit Horvath, Irina Astafieva, Signe Erickson, Kathleen Cogan Farinas
-
Patent number: 9877977Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: May 4, 2017Date of Patent: January 30, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9873700Abstract: Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.Type: GrantFiled: May 29, 2014Date of Patent: January 23, 2018Assignee: Plexxikon Inc.Inventors: Chao Zhang, Klaus-Peter Hirth, Prabha N. Ibrahim, Marika Nespi, Songyuan Shi, Wayne Spevak, Gaston G. Habets, Elizabeth A. Burton
-
Patent number: 9867823Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 22, 2016Date of Patent: January 16, 2018Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Patent number: 9867839Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as joint conditions.Type: GrantFiled: February 21, 2017Date of Patent: January 16, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9861648Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.Type: GrantFiled: June 15, 2017Date of Patent: January 9, 2018Assignee: ANTECIP BOIVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9855213Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: May 18, 2017Date of Patent: January 2, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9827192Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: March 1, 2017Date of Patent: November 28, 2017Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9820488Abstract: The invention relates to compounds of the general formula (I) wherein the variable have the meanings as indicated in the claims, or a physiologically acceptable salt thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling endoparasites in warm-blooded animals.Type: GrantFiled: November 14, 2014Date of Patent: November 21, 2017Assignee: ELANCO TIERGESUNDHEIT AGInventors: Noëlle Gauvry, François Pautrat
-
Patent number: 9814713Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2 -(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.Type: GrantFiled: May 12, 2016Date of Patent: November 14, 2017Assignee: Signal Pharmaceuticals, LLCInventors: Hon-Wah Man, Jean Xu, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou, Ying Li, Lianfeng Huang, Daozhong Zou
-
Patent number: 9809577Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.Type: GrantFiled: December 11, 2014Date of Patent: November 7, 2017Assignee: Biogen MA Inc.Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
-
Patent number: 9802923Abstract: The present invention provides a process for the preparation of pazopanib of Formula Ia or salts, and intermediates thereof.Type: GrantFiled: December 17, 2013Date of Patent: October 31, 2017Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajesh Kumar, Prabhat Giri, Dhiren C. Barman, Asok Nath, Mohan Prasad
-
Patent number: 9796685Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.Type: GrantFiled: December 15, 2015Date of Patent: October 24, 2017Assignee: Signal Pharmaceuticals, LLCInventors: Nathan Andrew Boersen, Indrajit Ghosh, Lianfeng Huang, Daozhong Zou
-
Patent number: 9789128Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: February 22, 2017Date of Patent: October 17, 2017Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9779862Abstract: [object] A magnetization technique that enhances magnetic properties of an organic compound is provided without damaging properties of the organic compound or while maintaining the structure of the organic compound. [solution] The present disclosure is a method for manufacturing a magnetic substance composed of crystals of a magnetization target compound and an electron acceptor by combining the magnetization target compound with the electron acceptor; forming a solution by dissolving a mixture of the magnetization target compound and the electron acceptor in a solvent; maintaining the solution in a very low temperature state and allowing the solution to deposit the crystals of the magnetic target compound and the electron acceptor; and separating the crystals from the solvent.Type: GrantFiled: June 15, 2015Date of Patent: October 3, 2017Assignees: IHI Corporation, Yoshihiro IshikawaInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Patent number: 9763944Abstract: The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.Type: GrantFiled: October 19, 2016Date of Patent: September 19, 2017Assignee: Novartis AGInventors: Yanfeng Wang, Elisabeth Wehrle